These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 32634832)

  • 1. Prevalence of Potential Drug-Drug Interactions in Patients of the Swiss HIV Cohort Study in the Era of HIV Integrase Inhibitors.
    Deutschmann E; Bucher HC; Jaeckel S; Gibbons S; McAllister K; Scherrer AU; Braun DL; Cavassini M; Hachfeld A; Calmy A; Battegay M; Cipriani M; Elzi L; Young J; Lopez-Centeno B; Berenguer J; Khoo S; Moffa G; Marzolini C;
    Clin Infect Dis; 2021 Oct; 73(7):e2145-e2152. PubMed ID: 32634832
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevalence of Polypharmacy and Potential Drug-Drug Interactions Associated with Risk Factors in the Era of HIV Integrase Inhibitors: A Prospective Clinical Study.
    Altunal LN; Yagcı Caglayık D; Ozel AS; Tukenmez Tigen E; Sili U; Erturk Sengel B; Aydın M; Korten V
    AIDS Patient Care STDS; 2023 Mar; 37(3):138-145. PubMed ID: 36812461
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Burden of Exposure to Potential Interactions Between Antiretroviral and Non-Antiretroviral Medications in a Population of HIV-Positive Patients Aged 50 Years or Older.
    Ranzani A; Oreni L; Agrò M; van den Bogaart L; Milazzo L; Giacomelli A; Cattaneo D; Gervasoni C; Ridolfo AL
    J Acquir Immune Defic Syndr; 2018 Jun; 78(2):193-201. PubMed ID: 29767640
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevalence of comedications and effect of potential drug-drug interactions in the Swiss HIV Cohort Study.
    Marzolini C; Elzi L; Gibbons S; Weber R; Fux C; Furrer H; Chave JP; Cavassini M; Bernasconi E; Calmy A; Vernazza P; Khoo S; Ledergerber B; Back D; Battegay M;
    Antivir Ther; 2010; 15(3):413-23. PubMed ID: 20516560
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevalence, beliefs and impact of drug-drug interactions between antiretroviral therapy and illicit drugs among people living with HIV in Spain.
    Castro-Granell V; Garin N; Jaén Á; Cenoz S; Galindo MJ; Fuster-RuizdeApodaca MJ
    PLoS One; 2021; 16(11):e0260334. PubMed ID: 34797882
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Potential drug-drug interactions in the era of integrase strand transfer inhibitors: a cross-sectional single-center study in Japan.
    Kunimoto Y; Matamura R; Ikeda H; Fujii S; Kimyo T; Kitagawa M; Nakata H; Kobune M; Miyamoto A; Fukudo M
    J Pharm Health Care Sci; 2021 Dec; 7(1):43. PubMed ID: 34847955
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of age with polypharmacy and risk of drug interactions with antiretroviral medications in HIV-positive patients.
    Tseng A; Szadkowski L; Walmsley S; Salit I; Raboud J
    Ann Pharmacother; 2013 Nov; 47(11):1429-39. PubMed ID: 24285760
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ageing with HIV: medication use and risk for potential drug-drug interactions.
    Marzolini C; Back D; Weber R; Furrer H; Cavassini M; Calmy A; Vernazza P; Bernasconi E; Khoo S; Battegay M; Elzi L;
    J Antimicrob Chemother; 2011 Sep; 66(9):2107-11. PubMed ID: 21680580
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Polypharmacy and potential drug-drug interactions among people living with HIV in the era of integrase strand transfer inhibitor-based antiretroviral therapy.
    Peng AT; Huang SH; Lee HY; Wu PY; Kuo HY; Hung CC
    Int J Antimicrob Agents; 2024 Feb; 63(2):107067. PubMed ID: 38141835
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevalence and nature of potential drug-drug interactions among hospitalized HIV patients presenting with suspected meningitis in Uganda.
    Eneh PC; Hullsiek KH; Kiiza D; Rhein J; Meya DB; Boulware DR; Nicol MR
    BMC Infect Dis; 2020 Aug; 20(1):572. PubMed ID: 32758158
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Prevalence of Drug-Drug Interactions with Antiretroviral Therapy in Human Immunodeficiency Virus-Infected Patients in the Intensive Care Unit.
    Johnston JP; Heavner MS; Liu M; Casal GLH; Akgün KM
    J Pharm Pract; 2023 Apr; 36(2):322-328. PubMed ID: 34587846
    [No Abstract]   [Full Text] [Related]  

  • 12. Polypharmacy and drug-drug interactions in older and younger people living with HIV: the POPPY study.
    Halloran MO; Boyle C; Kehoe B; Bagkeris E; Mallon P; Post FA; Vera J; Williams I; Anderson J; Winston A; Sachikonye M; Sabin C; Boffito M
    Antivir Ther; 2019; 24(3):193-201. PubMed ID: 30700636
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevalence of Potential Drug-drug Interactions With Ritonavir-containing COVID-19 Therapy in the United States: An Analysis of the National Health and Nutrition Examination Survey.
    Igho-Osagie E; Brzozowski K; Jin H; Brown J; Williams MG; Puenpatom A
    Clin Ther; 2023 May; 45(5):390-399.e4. PubMed ID: 37032225
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Polypharmacy and Drug-Drug Interactions in People Living With Human Immunodeficiency Virus in the Region of Madrid, Spain: A Population-Based Study.
    López-Centeno B; Badenes-Olmedo C; Mataix-Sanjuan Á; McAllister K; Bellón JM; Gibbons S; Balsalobre P; Pérez-Latorre L; Benedí J; Marzolini C; Aranguren-Oyarzábal A; Khoo S; Calvo-Alcántara MJ; Berenguer J
    Clin Infect Dis; 2020 Jul; 71(2):353-362. PubMed ID: 31428770
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Frequency and severity of potential drug interactions in a cohort of HIV-infected patients Identified through a Multidisciplinary team.
    Molas E; Luque S; Retamero A; Echeverría-Esnal D; Guelar A; Montero M; Guerri R; Sorli L; Lerma E; Villar J; Knobel H
    HIV Clin Trials; 2018 Feb; 19(1):1-7. PubMed ID: 29179644
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potential drug-drug interactions between antiretroviral drugs and comedications, including dietary supplements, among people living with HIV: A clinical survey.
    Tinggaard M; David KP; Gerstoft J; Hansen AE; Kirk O; Lebech AM; Lindhardt BØ; Rose MV; Ryom L; Weis N; Benfield T
    HIV Med; 2023 Jan; 24(1):46-54. PubMed ID: 35521975
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevalence of drug-drug interactions in the era of HIV integrase inhibitors: a retrospective clinical study.
    Baecke C; Gyssens IC; Decoutere L; van der Hilst JCH; Messiaen P
    Neth J Med; 2017 Jul; 75(6):235-240. PubMed ID: 28741582
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk of potential drug-drug interactions among Brazilian elderly: a population-based, cross-sectional study.
    Secoli SR; Figueras A; Lebrão ML; de Lima FD; Santos JL
    Drugs Aging; 2010 Sep; 27(9):759-70. PubMed ID: 20809665
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Do ART and Chemsex Drugs Get Along? Potential Drug-Drug Interactions in a Cohort of People Living with HIV Who Engaged in Chemsex: A Retrospective Observational Study.
    De La Mora L; Nebot MJ; Martinez-Rebollar M; De Lazzari E; Tuset M; Laguno M; Ambrosioni J; Miquel L; Blanch J; Ugarte A; Torres B; González-Cordón A; Inciarte A; Chivite I; Short D; Salgado E; Martinez E; Blanco JL; Mallolas J
    Infect Dis Ther; 2022 Dec; 11(6):2111-2124. PubMed ID: 36173594
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predictors of clinically significant drug-drug interactions among patients treated with nonnucleoside reverse transcriptase inhibitor-, protease inhibitor-, and raltegravir-based antiretroviral regimens.
    Patel N; Abdelsayed S; Veve M; Miller CD
    Ann Pharmacother; 2011 Mar; 45(3):317-24. PubMed ID: 21386025
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.